Shares in Catalent (NYSE:CTLT) jumped more than 20% last week after the company beat expectations on Wall Street with its fiscal 3rd quarter results. The Somersert, N.J.-based company posted profits of $26 million, or 21¢ per share, on sales of $532.6 million for the 3 months ended March 31, for bottom-line growth of 143% on sales growth […]
Valeant posts Q1 profit thanks to tax benefit, raises guidance
Shares in Valeant Pharmaceuticals (NYSE:VRX) rose more than 25% today after the company met earnings expectations on Wall Street, but missed on revenue with its 1st quarter results. The Canada-based company posted profits of $628 million, or $1.79 per share, on sales of $2.11 billion for the 3 months ended March 31, for bottom-line growth […]
Study: pSivida’s Durasert lessens recurrence of uveitis through 12 months
pSivida (NSDQ:PSDV) touted 1-year follow-up data yesterday for the company’s Durasert 3-year treatment of posterior segment uveitis. The data, which was presented at the Association for Research in Vision and Ophthalmology annual meeting, is from pSivida’s 1st phase III trial. The data showed that the 3-year uveitis implant significantly reduced the recurrence of posterior segment uveitis […]
First uveitis patient treated with Eyevensys’ electro-transfection system
Private biotech Eyevensys said today that it treated the 1st patient in a first-in-human phase I/II trial of its lead candidate, EYS606, for the treatment of non-infectious uveitis. The patient was treated in Paris at the Cochin Institute using the company’s EyeCET technology. The EyeCET platform is an electro-transfection injection system that delivers non-viral plasmids to encode […]
Allergan, Medicines360 tout 4-year pivotal data for Liletta intrauterine contraceptive
Allergan (NYSE:AGN) and women’s health nonprofit pharma company Medicines360 touted 4-year data today from an ongoing pivotal trial for its Liletta intrauterine contraceptive. The system is approved for the prevention of pregnancy for up to 3 years. More than 1,500 women ranging from 16 to 45 years old were enrolled and studied in the group’s […]
Sanofi ties drug price increases to healthcare inflation
Insulin makers have faced questioning this year for their drug pricing practices – a class-action lawsuit filed in the U.S. District Court of Massachusetts in January alleges that Sanofi (NYSE:SNY), Novo Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY) conspired to raise their list prices to get access to pharmacy benefit managers’ preferred lists, instead of competing with each other […]
Pfizer collaborates to improve access to injectable contraceptive
Pfizer (NYSE:PFE) said yesterday that it inked a multi-year extension of its collaboration with the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation to improve access to the company’s injectable contraceptive, Sayana Press, for women in developing countries. The pharma giant’s product uses Becton Dickinson‘s (NYSE:BDX) Uniject delivery system to administer a long-acting, […]
Systemic therapy beats Bausch & Lomb implant in NIH uveitis study
Systemic therapy of corticosteroids and immunosuppressants better preserved vision in patients with uveitis compared to Bausch & Lomb‘s long-lasting corticosteroid intraocular implant in a clinical trial supported by the National Eye Institute, a branch of the National Institutes of Health. In 7 years, visual acuity remained stable in patients receiving systemic therapy and declined by […]
Nanoscale ‘slingshot’ shoots drug to infection site
Researchers from the University of Rome Tor Vergata and the University of Montreal have reported the design and synthesis of a nanoscale molecular slingshot made of DNA that could potentially shoot and target drugs to specific regions of the human body. The slingshot is made of a synthetic DNA strand that can be loaded with […]
Ocular’s Dextenza meets primary endpoints in Phase III trial
Shares in Ocular Therapeutix (NSDQ:OCUL) rose more than 5% today after the company said its Dextenza post-surgical ocular pain relief implant met primary endpoints in the company’s most recent Phase III trial. The hydrogel plug, inserted into a patient’s tear duct, is designed to deliver a sustained dose of dexamethasone over 4 weeks following ophthalmic surgery. […]